Determination of fraction unbound docetaxel using microequilibrium dialysis

被引：16

作者：

Acharya, MR

Baker, SD

Verweij, J

Figg, WD ^{[1
]}

Sparreboom, A

机构：

[1] NCI, Clin Pharmacol Res Ctr, Bethesda, MD 20892 USA

[2] Johns Hopkins Univ, Sidney Kimmel Co mprehens Canc Ctr, Div Expt Therapeut, Baltimore, MD USA

[3] Erasmus Univ MC, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands

来源：

ANALYTICAL BIOCHEMISTRY | 2004年 / 331卷 / 01期

关键词：

D O I：

10.1016/j.ab.2004.03.045

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：192 / 194

页数：3

共 9 条

[1] Comparative pharmacokinetics of weekly and every-three-weeks docetaxel [J].

Baker, SD ;

Zhao, M ;

Lee, CKK ;

Verweij, J ;

Zabelina, Y ;

Brahmer, JR ;

Wolff, AC ;

Sparreboom, A ;

Carducci, MA .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :1976-1983

[2] Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry [J].

Baker, SD ;

Zhao, M ;

He, P ;

Carducci, MA ;

Verweij, J ;

Sparreboom, A .

ANALYTICAL BIOCHEMISTRY, 2004, 324 (02) :276-284

[3] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer [J].

Bruno, R ;

Hille, D ;

Riva, A ;

Vivier, N ;

Huinnink, WWTB ;

van Oosterom, AT ;

Kaye, SB ;

Verweij, J ;

Fossella, FV ;

Valero, V ;

Rigas, JR ;

Seidman, AD ;

Chevallier, B ;

Fumoleau, P ;

Burris, HA ;

Ravclin, PM ;

Sheiner, LB .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :187-196

[4] Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel [J].

Bruno, R ;

Vivier, N ;

Veyrat-Follet, C ;

Montay, G ;

Rhodes, GR .

INVESTIGATIONAL NEW DRUGS, 2001, 19 (02) :163-169

[5] Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins [J].

Loos, WJ ;

Baker, SD ;

Verweij, J ;

Boonstra, JG ;

Sparreboom, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (04) :364-371

[6]

Nabholtz Jean-Marc, 2003, Clin Breast Cancer, V4, P187, DOI 10.3816/CBC.2003.n.023

[7] Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): Recent developments [J].

Simon, GR ;

Bunn, PA .

CANCER INVESTIGATION, 2003, 21 (01) :87-104

[8] Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches [J].

ten Tije, AJ ;

Loos, WJ ;

Verweij, J ;

Baker, SD ;

Dinh, K ;

Figg, WD ;

Sparreboom, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) :509-510

[9]

Urien S, 1996, INVEST NEW DRUG, V14, P147

← 1 →